Abstract: The present application relates to the field of naked eye 3D technology, provides a method and a device for naked eye 3D displaying a vehicle instrument, which includes: collecting a real-time eye position of an operator in a real time, generating a corresponding real-time visual interweaving image according to the real-time eye position, and displaying the real-time visual interweaving image on a display interface; identifying whether the operator is engaged in human behavior, if so, obtaining human behavior information of the operator; predicting a deviation interval of the operator according to the human behavior information, and generating and caching a viewing angle image set corresponding to the deviation interval; and compensating in response to the real-time visual interweaving image on the display interface according to the viewing angle image set.

Abstract: Provided are a smart surface, a center console of a vehicle, and a vehicle. The smart surface includes a display device (10), a decorative cover plate (20) including a decorative pattern layer (21), a substrate layer (22), an optical adhesive layer (23), and a glass layer (24) stacked sequentially from top to bottom, an upper surface of the glass layer (24) being fitted to the optical adhesive layer (23), and a lower surface of the glass layer (24) being covered on the display device (10), and an AG fluorescent film (30) fitted to the decorative pattern layer (21), and the AG fluorescent film (30) is used for filtering ambient light or light emitted from the decorative pattern layer (21). The smart surface provided by the present application can reduce the obstruction of the image caused by the decorative pattern by providing the AG fluorescent film.

Abstract: In the invention, the minimum inhibitory concentrations of human-originated EGF domain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity. It has been shown that the human-originated EGF domain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by silver staining that the human-originated EGF domain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia. The amino acid sequences of the human-originated EGF domain proteins are the one described in SEQ ID NO: 1 in the sequence listing, or those having homology of over 50% to the amino acid sequence described in SEQ ID NO: 1.

Abstract: In the invention, the minimum inhibitory concentrations of human coagulation factor light-chain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity and the inhibiting effect of the human coagulation factor light-chain proteins against different Gram-negative bacteria is detected with the in vivo antibacterial activity. It has been shown that human coagulation factor light-chain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by mass spectrometry and silver staining that human coagulation factor light-chain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia.

Abstract: In the invention, the minimum inhibitory concentrations of human-originated EGF domain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity. It has been shown that the human-originated EGF domain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by silver staining that the human-originated EGF domain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia. The amino acid sequences of the human-originated EGF domain proteins are the one described in SEQ ID NO: 1 in the sequence listing, or those having homology of over 50% to the amino acid sequence described in SEQ ID NO: 1.

Abstract: In the invention, the minimum inhibitory concentrations of human coagulation factor light-chain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity and the inhibiting effect of the human coagulation factor light-chain proteins against different Gram-negative bacteria is detected with the in vivo antibacterial activity. It has been shown that human coagulation factor light-chain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by mass spectrometry and silver staining that human coagulation factor light-chain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia.